UBS AM
ESPR

UBS AM’s Esperion Therapeutics ESPR Stock Holding History

UBS AM’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-249,500
Closed -$246K – 2387
2025
Q2 		$246K Buy
+249,500
New +$250K ﹤0.01% 2545
2023
Q3 		– Sell
-111,482
Closed -$177K – 2619
2023
Q2 		$177K Hold
111,482
– – ﹤0.01% 2585
2023
Q1 		$177K Buy
111,482
+39,787
+55% +$205K ﹤0.01% 2585
2022
Q4 		$447K Buy
+71,695
New +$513K ﹤0.01% 2218
2021
Q4 		– Sell
-33,476
Closed -$403K – 2870
2021
Q3 		$403K Hold
33,476
– – ﹤0.01% 2562
2021
Q2 		$708K Buy
33,476
+6,240
+23% +$150K ﹤0.01% 2389
2021
Q1 		$764K Buy
27,236
+4,235
+18% +$125K ﹤0.01% 2206
2020
Q4 		$598K Hold
23,001
– – ﹤0.01% 2232
2020
Q3 		$855K Sell
23,001
-207
-0.9% -$8.2K ﹤0.01% 1905
2020
Q2 		$1.19M Buy
23,208
+3,904
+20% +$163K ﹤0.01% 1727
2020
Q1 		$609K Sell
19,304
-1,866
-9% -$98.5K ﹤0.01% 1899
2019
Q4 		$1.26M Buy
21,170
+88
+0.4% +$3.96K ﹤0.01% 1801
2019
Q3 		$773K Buy
21,082
+3,594
+21% +$142K ﹤0.01% 2078
2019
Q2 		$814K Buy
17,488
+2,498
+17% +$117K ﹤0.01% 1985
2019
Q1 		$602K Buy
14,990
+1,097
+8% +$49.2K ﹤0.01% 2034
2018
Q4 		$639K Buy
13,893
+4,493
+48% +$216K ﹤0.01% 1897
2018
Q3 		$417K Buy
9,400
+3,300
+54% +$152K ﹤0.01% 2159
2018
Q2 		$239K Sell
6,100
-60,674
-91% -$3.07M ﹤0.01% 2400
2018
Q1 		$4.83M Buy
66,774
+1,480
+2% +$109K ﹤0.01% 1162
2017
Q4 		$4.3M Buy
65,294
+25,396
+64% +$1.37M ﹤0.01% 1167
2017
Q3 		$2M Buy
39,898
+700
+2% +$33.8K ﹤0.01% 1405
2017
Q2 		$1.81M Sell
39,198
-147,954
-79% -$5.44M ﹤0.01% 1403
2017
Q1 		$6.61M Buy
+187,152
New +$4.29M 0.01% 975
2015
Q3 		– Sell
-5,700
Closed -$466K – 2679
2015
Q2 		$466K Buy
5,700
+1,600
+39% +$157K ﹤0.01% 2105
2015
Q1 		$380K Buy
+4,100
New +$265K ﹤0.01% 2125

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

UBS AM's ESPR Position: Q3 2025 in Review

UBS AM sold out of Esperion Therapeutics (ESPR) in Q3 2025, closing a stake of 249,500 shares — an estimated $246K sold.

UBS AM first reported a position in ESPR in Q1 2015 and held it in 25 quarters. The position peaked at $6.61M in Q1 2017. 188 funds tracked by Wall St. Rank hold ESPR as of Q3 2025.

  • UBS AM reported no remaining Esperion Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS AM sold 249,500 Esperion Therapeutics shares in Q3 2025, an estimated $246K.
  • UBS AM first reported a position in Esperion Therapeutics in Q1 2015 and held it in 25 quarters.
  • UBS AM's Esperion Therapeutics position peaked at $6.61M in Q1 2017.
  • 188 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2025.

Based on UBS AM's 13F filing for Q3 2025, filed 14 Nov 2025.